男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影

China sets more funds for HIV research

Updated: 2011-09-15 07:28

By Shan Juan (China Daily)

  Comments() Print Mail Large Medium  Small 分享按鈕 0

BANGKOK - China invested more than $18 million in HIV vaccine research and development in 2010, becoming the third largest contributor globally, after the United States and the European Union, according to a report endorsed by UNAIDS.

Internationally, HIV vaccine research and development (R&D) funding stood at $859 million last year, $9 million less than 2009, while China increased its spending by nearly $4 million over the same period, said the global report issued jointly by international organizations including AIDS Vaccine Advocacy Coalition (AVAC) and Intentional AIDS Vaccine Initiative.

"The long-term nature of vaccine research will require sustained investments globally and more developing countries like China are expected to shoulder more responsibilities," Kevin Fisher, the coalition's policy director said at the 2011 AIDS Vaccine Conference, which opened on Tuesday.

Unfortunately, overall global funding for HIV R&D has flattened out since 2000 and some early supporters, such as Canada and Sweden, have cut back, said the report. In the EU, a major contributor, funding has declined by 23 per cent since 2007.

In contrast, the Chinese government has pledged to further boost funding for HIV vaccine development by at least 20 percent in five years, according to Shao Yiming, director of the virology and immunology department of the National Center for AIDS/STD Control and Prevention.

Currently, China has four major HIV vaccine candidates under development on the mainland, all financed by the government.

"Compared with many developed countries like the US, which has dozens of HIV vaccine candidates under development, China needs more to have a better chance of success," Shao said.

His team is now waiting for approval from China's drug authorities to enter the second phase of the clinical trial for their HIV vaccine candidate, Tiantan.

Usually a vaccine has to undergo three phases of human trials before being licensed for use, experts said. The first two phases mainly test its safety and the third mainly its efficacy.

By May, 24 HIV vaccine candidates had entered the human trial stages across the world, including Tiantan, which is the only one from China to have reached that point.

Shao urged the Chinese government to regularly increase funding for vaccine development, particularly when some attention has been diverted to new prevention measures with proven efficacy.

"An effective and affordable vaccine is unanimously recognized as the ultimate weapon against HIV/AIDS worldwide," he said.

"The funding and human resources for vaccine R&D in China should be diversified and stakeholders like charities and industry should join in the effort."

Currently, all such studies on the mainland are funded and organized by the government, he said.

Half of the resources come from non-public sectors like pharmaceutical companies and philanthropic organizations, according to Shao.

As well, Kevin Fisher called on the Chinese government to be more transparent and to collaborate with international researchers in HIV vaccine development.

He said the Chinese authorities were usually reluctant to share relevant information, such as the amount of investment, with international stakeholders.

主站蜘蛛池模板: 昔阳县| 桦川县| 新泰市| 徐水县| 罗江县| 呼图壁县| 兰考县| 库尔勒市| 琼结县| 肃宁县| 平遥县| 岢岚县| 长岭县| 丹棱县| 宜宾市| 凤庆县| 苏尼特左旗| 加查县| 长治市| 滁州市| 禄丰县| 平顶山市| 雅安市| 商河县| 南昌市| 冀州市| 朝阳市| 揭阳市| 枣庄市| 周至县| 阳曲县| 佛冈县| 聂荣县| 南华县| 江孜县| 综艺| 承德市| 神池县| 疏勒县| 望谟县| 桂东县| 海城市| 新巴尔虎右旗| 金乡县| 广丰县| 历史| 梨树县| 堆龙德庆县| 安西县| 汝南县| 曲阳县| 乌拉特后旗| 兴隆县| 长治市| 贺兰县| 渝北区| 兴国县| 错那县| 闵行区| 富民县| 原阳县| 青河县| 海阳市| 黔西县| 响水县| 武定县| 正蓝旗| 永善县| 类乌齐县| 兴安盟| 虞城县| 兰溪市| 图木舒克市| 恭城| 庆城县| 虎林市| 花莲市| 黑河市| 东阳市| 许昌市| 白玉县| 资阳市|